These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. Rooney M; Pfister W; Mahoney M; Nelson M; Yeager J; Steidle C J Sex Med; 2009 Feb; 6(2):520-34. PubMed ID: 19138370 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Williams G; Abbou CC; Amar ET; Desvaux P; Flam TA; Lycklama à Nijeholt GA; Lynch SF; Morgan RJ; Müller SC; Porst H; Pryor JP; Ryan P; Witzsch UK; Hall MM; Place VA; Spivack AP; Gesundheit N Br J Urol; 1998 Jun; 81(6):889-94. PubMed ID: 9666777 [TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Hellstrom WJ; Bennett AH; Gesundheit N; Kaiser FE; Lue TF; Padma-Nathan H; Peterson CA; Tam PY; Todd LK; Varady JC; Place VA Urology; 1996 Dec; 48(6):851-6. PubMed ID: 8973666 [TBL] [Abstract][Full Text] [Related]
11. [Priapism after intracavernous injection of PgE1 in two cases of impotence following total cysto-prostatectomy]. Llopis J; Romero JA; Gutiérrez R; Alvarez R; Talbot R; Vendrell JR; Barranco MA; Carretero P J Urol (Paris); 1995; 101(2):104-6. PubMed ID: 8522852 [TBL] [Abstract][Full Text] [Related]
12. [Iatrogenic priapism caused by intracavernous injection of vasoactive drugs in the treatment of impotence]. Bondil P Presse Med; 1986 Apr; 15(14):665. PubMed ID: 2939440 [No Abstract] [Full Text] [Related]
13. Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction. English JC; King DH; Foley JP J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):801-3. PubMed ID: 9810901 [No Abstract] [Full Text] [Related]
14. Intracorporeal phenylephrine in the treatment of priapism. Muruve N; Hosking DH J Urol; 1996 Jan; 155(1):141-3. PubMed ID: 7490814 [TBL] [Abstract][Full Text] [Related]
15. An update on the drug safety of treating erectile dysfunction. Gul M; Serefoglu EC Expert Opin Drug Saf; 2019 Oct; 18(10):965-975. PubMed ID: 31433252 [No Abstract] [Full Text] [Related]
16. Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Schramek P; Dorninger R; Waldhauser M; Konecny P; Porpaczy P Br J Urol; 1990 Jan; 65(1):68-71. PubMed ID: 2310934 [TBL] [Abstract][Full Text] [Related]
17. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy. Engel JD; McVary KT Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580 [TBL] [Abstract][Full Text] [Related]
18. Deep venous thrombosis and venous thrombophlebitis associated with alprostadil treatment for erectile dysfunction. Barthelmes L; Chezhian C; Aihaku EK Int J Impot Res; 2002 Jun; 14(3):199-200. PubMed ID: 12058249 [TBL] [Abstract][Full Text] [Related]
20. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group. Williams G; Abbou CC; Amar ET; Desvaux P; Flam TA; Lycklama à Nijeholt GA; Lynch SF; Morgan RJ; Müller SC; Porst H; Pryor JP; Ryan P; Witzsch UK; Hall MM; Place VA; Spivack AP; Todd LK; Gesundheit N Br J Urol; 1998 Dec; 82(6):847-54. PubMed ID: 9883223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]